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OBJECTIVE — Identiﬁcation of asymptomatic patients with type 2 diabetes at increased risk
for coronary artery disease (CAD) remains a challenge. We evaluated the potential of carotid
intima-media thickness (CIMT) for prediction of abnormal myocardial perfusion in this
population.
RESEARCH DESIGN AND METHODS — CIMT and SPECT myocardial perfusion
imagingwereassessedin98asymptomaticpatientswithtype2diabetes.AnincreasedCIMTwas
deﬁned as 75th percentile of reference values.
RESULTS — Increased CIMT was an independent predictor of the extent of abnormal perfu-
sion(P0.001).InpatientswithincreasedCIMTascomparedwithpatientswithnormalCIMT,
abnormal perfusion (75 vs. 9%) and severely abnormal perfusion (28 vs. 3%) were observed
more frequently.
CONCLUSIONS — Increased CIMT was signiﬁcantly related to the presence and extent of
abnormal myocardial perfusion. Assessment of CIMT may be useful to identify asymptomatic
patients with type 2 diabetes at higher risk for CAD.
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I
dentiﬁcation of asymptomatic patients
with type 2 diabetes at increased risk for
coronary artery disease (CAD) remains a
challenge. In the current study, we evalu-
ated the potential of carotid intima-media
thickness (CIMT) to identify asymptomatic
patients with type 2 diabetes at higher risk
for abnormal myocardial perfusion.
RESEARCH DESIGN AND
METHODS— Prospectively, 98 con-
secutive asymptomatic patients with
type 2 diabetes (1) were recruited from
a routine outpatient diabetes clinic and
referred for cardiovascular risk stratiﬁ-
cation. Asymptomatic status was con-
ﬁrmedusingtheRosequestionnaire(2).
All patients underwent myocardial per-
fusion imaging by single-photon emis-
sion computed tomography (SPECT)
and CIMT assessment.
SPECT data acquisition and data
analysis




pharmacological stress and rest, accord-
ing to protocols described previously (3).
Using a 17-segment model tracer, up-
take in each segment was evaluated by two
observers in consensus by use of a ﬁve-
point scoring system (4). The total seg-
mental score during stress was used to
determine the extent of abnormal perfu-
sion as reﬂected by the summed stress
score (SSS). Abnormal perfusion was de-
ﬁned as SSS 3 and severely abnormal
perfusion as SSS 8.
CIMT measurement and data
analysis
CIMT was assessed using high-resolution
B-mode ultrasound with a 10-MHz linear
transducer, with an automatic boundary
detection system (Art Lab-Esaote-Picus,
Genova, Italy). Measurements were per-
formed by an experienced sonographer
blinded to clinical information (5). Mean
CIMT was assessed throughout 10-mm
segments, at four angles, across the far
wall of the right and left common carotid
artery (CCA). The average of the mean
CIMTvaluesofthefoursegmentswascal-
culated to determine the mean right and
left CIMT per patient.
CIMTvalues75thpercentile(perage
and sex category) are deﬁned as increased,
indicating elevated cardiovascular risk (5).
In the current study, the mean CIMT was
compared with reference values from the
Multi-Ethnic Study of Atherosclerosis (5).
Patients were thereby stratiﬁed as having
normal CIMT (CIMT 75th percentile) or
increasedCIMT(CIMT75thpercentilein




increased CIMT. The independent T test
was used to assess the difference in mean
SSS between the two groups.
Thereafter, univariate analysis of base-
line characteristics including age, positive
family history of CAD, smoking, hyperten-
sion, hypercholesterolemia, BMI, nephrop-
athy (urine albumin/creatinine 3.5 mg/
mmol), fasting glucose, glycated hemo-
globin (by chromatography) (6), retinopa-
thy, peripheral arterial disease, and in-
creased CIMT was performed to identify
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normal perfusion (SSS). Subsequently,
risk factors with a P value 0.05 were
included in a linear multiple regression
model to identify independent predictors
of SSS. Finally, the prevalence of abnor-
mal perfusion (SSS  3) and severely ab-
normal perfusion (SSS  8) was
compared between patients with normal
and increased CIMT.
RESULTS— Brieﬂy, the mean age of
the study population was 54  11 years,
with the majority of patients being male
(n50,51%).MeanSSSwas3.14.2in
the total population. Overall, 34 patients
(35%) showed abnormal perfusion
(SSS  3), including severely abnormal
perfusion (SSS  8) in 14 patients (14%).
Average CIMT was 0.68  0.12 mm.
Comparison with reference values re-
vealed normal CIMT in 60 patients
(61%),whileintheremaining38patients
(39%) an increased CIMT value was ob-
served in at least one CCA.
CIMT versus extent of abnormal
perfusion
The mean SSS increased signiﬁcantly
from 1.2  2.1 in patients with normal
CIMT to 5.6  4.6 in patients with in-
creased CIMT (P  0.001).
Age, smoking, hypertension, ne-
phropathy, and increased CIMT were
identiﬁed as potential predictors of SSS
on SPECT, in a univariate regression
model. Importantly, after adjustment for
age, smoking, hypertension, and ne-
phropathy in a multivariate model, in-
creased CIMT remained a signiﬁcant
predictor of SSS (P  0.001) (4.41
[95% CI 3.05–5.76]).
CIMT versus prevalence of abnormal
perfusion
Abnormal perfusion was present in 9% of
patientswithnormalCIMTversus75%of
patients with increased CIMT (Fig. 1A).
Notably, prevalence of severely abnormal
perfusion increased from 3% in patients
with normal CIMT to 28% in those with
increased CIMT (Fig. 1B).
CONCLUSIONS— The prognostic
value of SPECT imaging has been con-
ﬁrmed in diabetic patients (7). In partic-
ular, a favorable cardiovascular prognosis
has been described in patients with nor-
malmyocardialperfusion,whereassignif-
icantly higher adverse event rates were
observed in patients with severely abnor-
mal perfusion (8). SPECT has therefore
been proposed as a screening tool for
identiﬁcation of asymptomatic diabetic
patients with obstructive CAD (9). How-
ever, considering the high global preva-
lenceoftype2diabetes,abroadscreening
strategy of all asymptomatic patients us-
ing SPECT perfusion imaging does not
appear feasible or cost-effective (10). The
American Heart Association/American
Diabetes Association therefore initially
suggested more aggressive medical treat-
ment and assessment of CAD only in the
presenceoftwoadditionalriskfactors(9).
Nonetheless, baseline analysis of SPECT
data in the Detection of Ischemia in
Asymptomatic Diabetics Study demon-
stratedthataselectionstrategybasedona
minimum of two additional risk factors
underestimates the presence of abnormal
perfusioninalargeproportionofpatients
(41%) (11). Accordingly, the key ques-
tion remains how asymptomatic diabetic
patients with severe CAD should be iden-
tiﬁed from the general diabetic popu-
lation.
Assessment of CIMT has been previ-
ously proposed for this purpose (12).
Moreover, the truly noninvasive, inex-
pensive, and radiation-free nature of
CIMTmayrepresentanimportantadvan-
tage over other suggested screening tech-
niques such as coronary calcium scoring
(5). However, the relation of CIMT with
CAD has not been fully established in
asymptomatic diabetic patients. In the
current study, increased CIMT was
shown to be a strong predictor of the ex-
tent of abnormal perfusion and improved
identiﬁcationofpatientswithseverelyab-
normal perfusion (28%). Normal CIMT
values on the other hand were associated
with a low risk for abnormal perfusion.
Importantly, only few asymptomatic dia-
betic patients with normal CIMT values
had severely abnormal perfusion (3%).
However, it must be acknowledged that a
nondiabetic control group was not avail-
able for comparison. Also, patients were
referred from a diabetes clinic and may
thus represent a more high-risk group
than the general asymptomatic popula-
tionwithdiabetes.Nevertheless,ourﬁnd-
ings suggest that initial risk stratiﬁcation
usingCIMTmayallowselectivereferralof
asymptomatic patients with type 2 diabe-
tes requiring further imaging and intensi-
ﬁcation of therapy, thereby improving
Figure 1—Relation between CIMT and myocardial perfusion imaging. Prevalence of abnormal perfusion (A) and severely abnormal perfusion (B)
was higher in patients with increased CIMT.
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